Disordered nocturnal prolactin regulation in women with breast cancer
- PMID: 922745
Disordered nocturnal prolactin regulation in women with breast cancer
Abstract
Mean 24-hr prolactin concentrations were determined in 25 female control subjects, 16 women with benign breast masses, and 23 subjects with breast cancer. This evaluation performed before breast surgery revealed significantly decreased (p less than 0.02) nocturnal (12 a.m. to 7 a.m.) prolactin concentrations in 12 postmenopausal breast cancer subjects that contrasted with significantly increased (p less than 0.05) nocturnal prolactin levels in five luteal-phase premenopausal women with breast cancers. Prolactin concentrations in patients with benign breast disease were not significantly different from control subjects. Two of the premenopausal breast cancer patients had marked preoperative elevations in their mean 24-hr prolactin levels, and they were two of the three subjects who have since expired. Nocturnal prolactin secretion was significantly decreased (p less than 0.03) in four premenopausal breast cancer patients when they were studied 1 year after surgery; however, it remained the same in the eight postmenopausal breast cancer patients similarly evaluated. Although disordered prolactin regulation has been found in these women with breast cancer, its role in the etiology and progression of human cancer is still uncertain.
Similar articles
-
Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease.Cancer Res. 1977 Dec;37(12):4655-9. Cancer Res. 1977. PMID: 922746
-
Serum hormones in human breast cancer subjects.Neoplasma. 1989;36(2):221-31. Neoplasma. 1989. PMID: 2497392
-
Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women.Cancer Res. 2006 Feb 15;66(4):2476-82. doi: 10.1158/0008-5472.CAN-05-3369. Cancer Res. 2006. PMID: 16489055
-
Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma.J Clin Invest. 1980 Mar;65(3):602-12. doi: 10.1172/JCI109705. J Clin Invest. 1980. PMID: 6986409 Free PMC article. Review.
-
Hormonal profiles in women with breast cancer.Obstet Gynecol Clin North Am. 1994 Dec;21(4):751-72. Obstet Gynecol Clin North Am. 1994. PMID: 7731646 Review.
Cited by
-
The Human Intermediate Prolactin Receptor I-tail Contributes Breast Oncogenesis by Targeting Ras/MAPK Pathway.Endocrinology. 2024 Apr 29;165(6):bqae039. doi: 10.1210/endocr/bqae039. Endocrinology. 2024. PMID: 38713636
-
Plasma lipids and prolactin in patients with breast cancer.Br J Cancer. 1986 Sep;54(3):439-46. doi: 10.1038/bjc.1986.195. Br J Cancer. 1986. PMID: 3756079 Free PMC article.
-
A comprehensive analysis of common genetic variation in prolactin (PRL) and PRL receptor (PRLR) genes in relation to plasma prolactin levels and breast cancer risk: the multiethnic cohort.BMC Med Genet. 2007 Dec 1;8:72. doi: 10.1186/1471-2350-8-72. BMC Med Genet. 2007. PMID: 18053149 Free PMC article.
-
Prolactin secretion and dehydroepiandrosterone sulphate plasma levels in women with benign breast disease.J Endocrinol Invest. 1989 Sep;12(8):549-52. doi: 10.1007/BF03350757. J Endocrinol Invest. 1989. PMID: 2531771
-
Host heterogeneity in female breast cancer: possible significance for pathophysiology, therapy, and prevention.Breast Cancer Res Treat. 1990 May;15(3):205-12. doi: 10.1007/BF01806357. Breast Cancer Res Treat. 1990. PMID: 2372572